What We're Reading: Page 202
Industry reads hand-picked by our editors
Mar 02, 2020
-
Axios
CDC lab for coronavirus test kits may have been contaminated
-
LifeSciVC
BioPharma M&A Drives More Efficient Resource Allocation
-
Endpoints News
Corporate development chief hits the exit at Biogen as aducanumab jitters roll on
-
Bloomberg
Chinese Biotech Censured for False Claim on Gilead’s Virus Drug
Feb 28, 2020
-
Forbes
Billionaire Robert Duggan’s New Biotech Chapter: An Antibiotics Quest
-
Xconomy
Biohaven's Migraine Pill Is the Latest CGRP Drug to Win the FDA's OK
-
Philadelphia Business Journal
Philadelphia gene therapy developer Passage Bio set to go public this week
-
ProPublica
Key Missteps at the CDC Have Set Back Its Ability to Detect the Potential Spread of Coronavirus
Feb 27, 2020
-
POLITICO
Trump puts Pence in charge of coronavirus response
-
Consumer Reports
GoodRx Shares Data With Google, Facebook & Others
-
FierceBiotech
Spark's CMO set to leave as post-Roche takeover exits continue
-
MIT Technology Review
If DNA is like software, can we just fix the code?
Feb 26, 2020
Feb 25, 2020
-
STAT
Safety concerns regarding Novartis’s new eye drug boost Regeneron stock
-
The Wall Street Journal
Drugmaker Moderna Delivers First Experimental Coronavirus Vaccine for Human Testing
-
The Philadelphia Inquirer
This isn’t a ‘biotech bubble,’ it’s ‘Philadelphia’s moment’ to become a center for gene therapy, says Penn-based CEO
-
POLITICO
White House fears coronavirus could shape Trump's 2020 fortunes
Feb 24, 2020
Feb 21, 2020
-
Philadelphia Business Journal
Spark Therapeutics co-founder Dr. Katherine High departing
-
STAT
In a cramped Kendall Square, biotech startups squeeze into shared labs
-
POLITICO
Problems with CDC coronavirus test delay expanded U.S. screening
-
The Boston Globe
Drop in cancer deaths reflect failures of our society. Really
Previous
